肺炎藥物市場規模、佔有率和成長分析（按產品、藥物類別、給藥途徑、感染方式、年齡層和地區）- 行業預測 2025-2032

2023 年肺炎藥物市場規模價值 112.9 億美元，預計將從 2024 年的 122.4 億美元成長到 2032 年的 233.3 億美元，預測期內（2025-2032 年）的複合年成長率為 8.4%。

全球肺炎藥物市場正在成長，這得益於肺炎盛行率的不斷上升，尤其是在老年人和免疫力缺乏中。社區型肺炎仍然是一個值得關注的問題，人們越來越意識到早期診斷和治療的重要性。這一背景促進了診斷技術和評估工具的進步，也加強了醫療保健提供者的治療指南。市場開發提供廣泛的抗生素、抗病毒藥物和支持性治療，同時注重個人化醫療以開發標靶治療。然而，抗生素抗藥性和醫療保健機會不平等等挑戰仍然存在。總體而言，持續的醫學進步和人口變化表明未來幾年肺炎治療市場將呈現良好的發展軌跡。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局
• 專利分析

肺炎治療藥物市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• 藥物
• 疫苗
• 氧氣療法

肺炎治療市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概況
• 抗生素
• 抗病毒藥物
• 抗真菌藥物

肺炎治療藥物市場規模（依給藥途徑及複合年成長率） (2025-2032)

• 市場概況
• 口服
• 腸外
• 吸入

肺炎治療藥物市場規模（按感染類型和複合年成長率） (2025-2032)

• 市場概況
• 院內獲得性肺炎（HAP）
• 社區型肺炎 (CAP)
• 人工呼吸器相關性肺炎 (VAP)

肺炎治療藥物市場規模（依年齡層分類）及複合年成長率（2025-2032）

• 市場概況
• 孩子們
• 成人
• 老年人

肺炎治療藥物市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

肺炎治療藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• GlaxoSmithKline plc（UK）
• AstraZeneca（UK）
• Novartis AG（Switzerland）
• Sanofi（France）
• Bayer AG（Germany）
• Eli Lilly and Company（USA）
• Abbott Laboratories（USA）
• Cipla Inc.（India）
• Lupin Pharmaceuticals Ltd.（India）
• Nabriva Therapeutics AG（Austria）
• Biotest AG（Germany）
• SetLance SRL（Italy）
• Biogen（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Johnson & Johnson（USA）
• Gilead Sciences, Inc.（USA）

結論和建議

Pneumonia Therapeutics Market size was valued at USD 11.29 billion in 2023 and is poised to grow from USD 12.24 billion in 2024 to USD 23.33 billion by 2032, growing at a CAGR of 8.4% during the forecast period (2025-2032).

The global pneumonia therapeutics market is experiencing growth driven by the rising pneumonia prevalence, particularly among the elderly and immunocompromised. Community-acquired pneumonia remains a notable concern, with increasing awareness surrounding the significance of early diagnosis and treatment. This impetus has spurred advancements in diagnostic techniques and assessment tools, enhancing treatment guidelines for healthcare providers. The market offers a diverse range of antibiotics, antiviral medications, and supportive therapies, alongside a focus on personalized medicine to develop targeted treatments. However, challenges such as antibiotic resistance and healthcare access disparities persist. Overall, ongoing medical advancements and demographic shifts indicate a promising trajectory for the pneumonia therapeutics market in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pneumonia Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pneumonia Therapeutics Market Segments Analysis

Global Pneumonia Therapeutics Market is segmented by Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel and region. Based on Product, the market is segmented into Drugs, Vaccines and Oxygen Therapy. Based on Drug Class, the market is segmented into Antibacterial Drugs, Antiviral Drugs and Antifungal Drugs. Based on Route of Administration, the market is segmented into Oral, Parenteral and Inhalation. Based on Mode of Infection, the market is segmented into Hospital-acquired Pneumonia (HAP), Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP). Based on Age Group, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pneumonia Therapeutics Market

The pneumonia therapeutics market is primarily fueled by the widespread prevalence of pneumonia, which poses a serious health threat, especially among at-risk groups including the elderly, infants, and those with weakened immune systems. As the incidence of pneumonia continues to increase globally, there is an urgent need for effective treatment options to combat this illness. This growing demand for innovative and efficient therapeutic solutions contributes significantly to the expansion of the pneumonia therapeutics market. Addressing the healthcare needs of vulnerable populations highlights the necessity for advancements in pneumonia treatment, ultimately driving market growth in this crucial sector.

Restraints in the Pneumonia Therapeutics Market

A significant limitation within the Pneumonia Therapeutics market is the issue of antibiotic resistance. The overuse and improper use of antibiotics have led to the development of drug-resistant bacterial strains, which pose a considerable challenge in effectively treating pneumonia. This growing resistance diminishes the effectiveness of existing treatment options and highlights an urgent need for innovative and alternative therapeutic approaches. As conventional antibiotics become less viable, healthcare providers and researchers are compelled to explore new strategies to combat pneumonia, underscoring the importance of addressing this restraint in the ongoing development of pneumonia treatments.

Market Trends of the Pneumonia Therapeutics Market

The pneumonia therapeutics market is witnessing a significant trend driven by an increased focus on drug development and research to address the challenges posed by drug-resistant bacterial strains. Pharmaceutical companies are channeling substantial investments into creating innovative antibiotics and alternative therapeutic strategies to enhance treatment efficacy. This momentum is underscored by the urgent need to combat the rising prevalence of antibiotic-resistant infections, which poses a serious public health threat. As a result, the landscape of pneumonia therapeutics is evolving, with stakeholders prioritizing advanced research initiatives that promise to redefine treatment paradigms and improve patient outcomes in the face of growing microbial resistance.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Pneumonia Therapeutics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Drugs
• Vaccines
• Oxygen Therapy

Global Pneumonia Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antibacterial Drugs
• Antiviral Drugs
• Antifungal Drugs

Global Pneumonia Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Inhalation

Global Pneumonia Therapeutics Market Size by Mode of Infection & CAGR (2025-2032)

• Market Overview
• Hospital-acquired Pneumonia (HAP)
• Community-acquired Pneumonia (CAP)
• Ventilator-associated Pneumonia (VAP)

Global Pneumonia Therapeutics Market Size by Age Group & CAGR (2025-2032)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Pneumonia Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Pneumonia Therapeutics Market Size & CAGR (2025-2032)

• North America (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • US
  • Canada
• Europe (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Drug Class, Route of Administration, Mode of Infection, Age Group, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nabriva Therapeutics AG (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SetLance SRL (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations